CORAL GABLES, Fla., March 31 Stiefel Laboratories, Inc.,the world's largest independent pharmaceutical company specializing indermatology, announced today that the company will donate up to $1 million inmatching funds to the Epidermolysis Bullosa Medical Research Foundation(EBMRF). The announcement comes in response to a challenge issued by CourteneyCox Arquette and her husband, David Arquette, to raise $1 million for thefoundation in just two weeks.
"We were thrilled to hear about the challenge Courteney Cox Arquette madeto her friends," said Todd Stiefel, executive vice president, Global Strategy."By matching dollar for dollar the amount they raise, we can help increaseawareness of Epidermolysis Bullosa and contribute to research that will leadto better treatments and hopefully find a cure for the various forms of thisterrible disease."
The match donation window for Stiefel's gift to EBMRF will run from theannouncement date, March 20, 2008, through April 14, 2008.
The pharmaceutical company announced its plans to contribute to EBMRFTuesday evening (March 25) via phone to guests at an invitation-onlyfundraiser at Eva Longoria Parker's new Hollywood restaurant Beso. Celebritiesin attendance at the star-studded party included Orlando Bloom, KateBeckinsale, Jennifer Aniston, sisters Jessica and Ashlee Simpson, and singerEve.
"The stakes have been raised," said Andrea Pett-Joseph, EBMRF. "Thanks toStiefel's pledge, every dollar donated until April 14 will actually be worthtwice as much and we are that much closer to a cure for EB and people affectedby the disease."
Epidermolysis Bullosa is a debilitating and life threatening disease thatcauses the skin to tear and blister from a slight touch or trauma, requiringdaily bandaging of the wounds. Wounds can cover the entire body and scarringcauses fusing of the toes and fingers. Esophageal scarring also makes eatingand breathing difficult and many of those affected develop a skin cancer earlyin life as a result of the disorder.
There is currently no cure for EB.
About Stiefel Laboratories, Inc.
Founded in 1847, Stiefel Laboratories (a privately held company) is theworld's largest independent pharmaceutical company specializing indermatology. The company manufactures and markets a variety of prescriptionand non-prescription dermatological products. Some of the newest and best-known brands include Duac(R) Topical Gel (clindamycin, 1% - benzoyl peroxide,5%) available in the Duac(R) Care System (CS); Evoclin(R) (clindamycinphosphate) Foam, 1%; Luxiq(R) (betamethasone valerate) Foam, 0.12%; MimyX(R)Cream; Olux(R) (clobetasol propionate) Foam, 0.05% and Olux-E(TM) (clobetasolpropionate) Foam, 0.05% also available in the Olux(R) / Olux-E(TM) COMPLETEPACK; Soriatane(R) (acitretin) Capsules available in the Soriatane(R) CKCONVENIENCE KIT; Verdeso(TM) (desonide) Foam, 0.05%; Brevoxyl(R)-4 Creamy Wash(benzoyl peroxide 4%) and Brevoxyl(R)-8 Creamy Wash (benzoyl peroxide 8%)packaged in the Brevoxyl(R) Acne Wash Kit; Extina(R) (ketoconazole) Foam, 2%;Oilatum(R) Cleansing Bar; Physiogel(R); Stieprox(R) (ciclopirox olamine);REVALESKIN(TM); and Sarna(R). Its wholly-owned global network is comprised ofmore than 30 subsidiaries, manufacturing plants in six countries, research anddevelopment facilities on four continents, and products marketed in more than100 countries around the world.
Stiefel Laboratories supplements its R&D efforts by seeking strategicpartnerships and acquisitions around the world. To learn more about StiefelLaboratories, Inc. visit www.stiefel.com.
SOURCE Stiefel Laboratories, Inc.